Pakistan Randomised Observational Trial to Evaluate Coronavirus Treatment (PROTECT) Underway

For Patient Enrollment Information click here

The pandemic of SARS Cov-2 (COVID-19) a condition characterized by array of symptoms leading to Severe Acute Respiratory Illness) began in the Central Chinese city of Wuhan (1). The first case was reported in December 2019 with symptoms resembling Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS). The pathogen was suspected to be from the family of enveloped positive-sense RNA viruses, characterized by club-like spikes that project from their surface, an unusually large RNA genome, and a unique replication strategy. As reported by Fehr AR et al in 2015, these viruses cause diseases in other mammals besides lethal respiratory tract infection in human beings. Chinese scientists sequenced the genome of this fast-emerging virus early in 2020 (2). It was named novel Corona virus 2019 causing an array of symptoms now referred to as COVID 19.

Considering the virulence potential and aggressive measures employed by the Chinese authorities to stem this deadly outbreak, World Health Organization has been issuing warnings before declaring it as a pandemic on March 11, 2020 (3).

The magnitude of problem is amplified by the absence of pharmaceutical solutions such as drugs and vaccines. For developing countries, the challenge is multifold (5).

A variety of drugs have been tested recently in search for a suitable cure including nafamostat, ribavirin, interferon, corticosteroids etc (2, 6). Chloroquine and hydroxychloroquine have been found to be efficient on COVID-19 and reported to be improving clinical symptoms in Chinese COVID-19 patients while similar effects have been demonstrated in French patients (6). Combining it with Oseltamivir  and Azithromycin has shown further promise in most recent studies (7). However, these findings are yet to be tested for the purpose in Pakistan where COVID-19 is being reported across. The rationale of such drug trial is merited by large population of 220 million and Pakistan’s proximity with Iran, one of the countries worst hit by ongoing pandemic. The PROTECT is on-going in Pakistan. 14 sites will be covered for the trials however, 4 site have been approved so far, and trial s have been conducted on 12 patients so far. This is the first Pre-peak trial.

PROTECT trial is evaluating the role of Hydroxychloroquine Phosphate/Sulfate, Oseltamivir and Azithromycin in COVID-19 infection through a comprehensive multicentre, cohort study at the centre of which is a multi-arm, multistage, open label randomised controlled trial. The on-going pandemic and limited evidence on effectiveness of chloroquine on local population warrant an adaptive trial design so that timely data analyses could promptly inform clinical strategy of containing COVID-19 (8). Hydroxychloroquine Phosphate/Sulfate (200 mg orally thrice a day for 5 days) vs Oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on Days 2-5) alone and in combination is being given to patients consenting to take part in the trial

The primary outcome will be clearing of coronavirus nucleic acid (COVID-19) from throat and nasal swabs checked by Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR). Those not consenting to randomization will be followed up for outcomes of COVID-19 infection with supportive care only.

The comprehensive cohort study is underway in four different centres across Pakistan.

For futher details, kindly click here
COMSTECH News & Announcements
  • 05June
    2020

  • 06May
    2020

    Click here to watch the recording of the Seminar.


  • April
    2020

    Coordinator General, COMSTECH Meets Minister of Science and Technology


  • 30April
    2020

    Prime Minister Visits MoST Exhibition on COVID-19-Related Products at COMSTECH


  • April
    2020

    The President of Pakistan in his capacity as Chairman COMSTECH has appointed, Prof. Dr. M. Iqbal Choudhary as the Coordinator General of COMSTECH.


  • 20Feb
    2020
    Mr. Samir Guliyev, 2nd Secretary (Deputy Head of Mission), Embassy of the Republic of Azerbaijan
  • 3 - 4Mar
    2020
    STIO 2026
  • 28-29Jan
    2020
    Sustainable-Cities
  • 14-15Jan
    2020
    OMSTECH-Inter-Islamic-network
  • 18-19Mar
    2019
    Steering-Committee
  • 27Nov
    2019
    science-diplomacy-2019
  • 19Nov
    2019
    CG
  • 18-19Nov
    2019

    Plants Genetics


  • Nov
    2019
    Robotics
  • Nov
    2019
    OIC Robotics Winner
  • 16Oct
    2019
    Brain-Machine Interface

    A Public Lecture by Dr. Naweed. I. Syed “Brain – Machine Interface: Future of Artificial Intelligence, Machine Learning and Singularity”


  • 27-31Oct
    2019
    OIC Robotics
  • 21Sep
    2019
    adviser

    COMSTECH delegate visits Malaysian institutions to accelerate implementation of OIC STI Agenda 2026


  • 20Sep
    2019
    FAO-COMSTECH

    Dr. Bo Zhou, the Senior Agricultural Officer at (FAO) had a meeting at COMSTECH head office Islamabad with Dr. Khurshid Hasanain (Adviser COMSTECH)


  • 04Sep
    2019
    comstech awards 2019
  • 18July
    2019

    QAU and COMSTECH organize International Symposium on Biodiversity and Big Health Data and 2nd Annual Meeting of Biodiversity and Health Big Data (BHBD) Alliance


  • May
    2019

    COMSTECH Awards


  • 29-31July,
    2019



Previous News & Announcements >>

Announcements from OIC Institutions
External News & Announcements
COMSTECH Secretariat, 33-Constitution Avenue, G-5/2, Islamabad Phone: (+92 51) 9220681 - Fax: (+92 51) 9211115 - COMSTECH Primary Email    |    COMSTECH Secondary Email